Beam Q1 FY26 net loss narrows 12.94% to $94.3 million

• Beam Therapeutics posted a Q1 net loss of $94.3 million, or $0.91 per share, narrowing from $108.3 million, or $1.23 per share, a year earlier.
• License and collaboration revenue climbed to $31.7 million from $7.5 million, while R&D expense increased to $104.5 million from $98.8 million.
• G&A costs rose to $34.4 million from $27.9 million; cash, cash equivalents, and marketable securities totaled $1.2 billion at March 31.
• For BEAM-302 in alpha-1 antitrypsin deficiency, updated Phase 1/2 data supported selecting 60 mg as optimal biological dose, with a global pivotal cohort expected to start in H2 2026.
• Risto-cel sickle cell disease data were published in New England Journal of Medicine; a U.S. BLA submission is expected as early as year-end 2026, with cash runway projected into mid-2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070700PRIMZONEFULLFEED9714459) on May 07, 2026, and is solely responsible for the information contained therein.